0000950170-24-009047.txt : 20240130
0000950170-24-009047.hdr.sgml : 20240130
20240130190004
ACCESSION NUMBER: 0000950170-24-009047
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240129
FILED AS OF DATE: 20240130
DATE AS OF CHANGE: 20240130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Savill Corrine
CENTRAL INDEX KEY: 0001837524
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39856
FILM NUMBER: 24580089
MAIL ADDRESS:
STREET 1: C/O CULLINAN ONCOLOGY, LLC
STREET 2: ONE MAIN STREET SUITE 520
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cullinan Oncology, Inc.
CENTRAL INDEX KEY: 0001789972
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 813867811
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 1350
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-410-4650
MAIL ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 1350
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Management, Inc.
DATE OF NAME CHANGE: 20210107
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Oncology, LLC
DATE OF NAME CHANGE: 20191001
4
1
ownership.xml
4
X0508
4
2024-01-29
0001789972
Cullinan Oncology, Inc.
CGEM
0001837524
Savill Corrine
C/O CULLINAN ONCOLOGY, INC.
ONE MAIN STREET, SUITE 1350
CAMBRIDGE
MA
02142
false
true
false
false
Chief Business Officer
true
Common Stock
2024-01-29
4
M
false
40000
4.3
A
205990
D
Common Stock
2024-01-29
4
S
false
40000
14.09
D
165990
D
Stock Option (Right to Buy)
4.30
2024-01-29
4
M
false
13997
0.00
D
2030-10-28
Common Stock
13997
0
D
Stock Option (Right to Buy)
4.30
2024-01-29
4
M
false
26003
0.00
D
2030-10-28
Common Stock
26003
110331
D
Transaction effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2023.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.00 to $14.54. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
25% of the shares vested on May 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter, becoming fully vested and exercisable on May 4, 2023.
25% of the shares vested on September 1, 2019, and the remaining shares vested in 36 equal monthly installments thereafter, becoming fully vested and exercisable on September 1, 2022.
/s/ Jacquelyn Sumer, Attorney-in-Fact
2024-01-30